Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.
Approval Alert | Axatilimab in Pediatric/Adult Chronic GVHD
Advertisement
Advertisement
Trending on CancerNetwork
1
Spotlighting the Top 10 FDA Oncology Approvals in 2025
2
A Look Back on the Top 10 Oncology Interviews in 2025
3
Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer
4
‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer
5